Added to YB: 2024-11-01
Pitch date: 2024-10-30
SOPH [bullish]
SOPHiA GENETICS SA
+36.81%
current return
Author Info
Two Natural Capital writes about markets, particularly focused on life sciences/biotech. Sign up for the newsletter.
Company Info
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
Market Cap
$292.4M
Pitch Price
$3.45
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.16
P/E
-3.86
EV/Sales
3.74
Sector
Health Care Technology
Category
growth
Sophia Genetics: The Benefits/Drawbacks of Sequencer Agnosticism $soph
SOPH: AI-driven genomic analysis platform for hospitals. 70% oncology focus. Sequencer-agnostic, multimodal data integration. Strong upsell potential (130% NDR in 2023). US growth 70% YoY. Challenges: long sales cycles, EMEA weakness. Trades at 2x EV/'25 sales. Growth expected to accelerate as new customers ramp up. Akre Capital invested.
Read full article (7 min)